Evidence map›Paper›PMID 35655072›Full record

ArticleScientific reports2022

Plasma extracellular vesicles bearing PD-L1, CD40, CD40L or TNF-RII are significantly reduced after treatment of AIDS-NHL.

Laura E Martínez, Shelly Lensing, Di Chang, Larry I Magpantay, Ronald Mitsuyasu, Richard F Ambinder, Joseph A Sparano, Otoniel Martínez-Maza, Marta Epeldegui

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Extracellular vesicles in malignant and normal B lymphocyte growth and development.Extracellular vesicles and circulating nucleic acids · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Laura E MartínezUCLA AIDS Institute and David Geffen School of Medicine, University of California, Los Angeles, Biomedical Sciences Research Building Room 173, Los Angeles, CA, 90095, USA.
Shelly LensingDepartment of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Di ChangDepartment of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Larry I MagpantayUCLA AIDS Institute and David Geffen School of Medicine, University of California, Los Angeles, Biomedical Sciences Research Building Room 173, Los Angeles, CA, 90095, USA.
Ronald MitsuyasuUCLA AIDS Institute and David Geffen School of Medicine, University of California, Los Angeles, Biomedical Sciences Research Building Room 173, Los Angeles, CA, 90095, USA.
Richard F AmbinderDivision of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, John Hopkins University, Baltimore, MD, USA.
Joseph A SparanoDivision of Hematology Oncology, Mount Sinai, NY, USA.
Otoniel Martínez-MazaUCLA AIDS Institute and David Geffen School of Medicine, University of California, Los Angeles, Biomedical Sciences Research Building Room 173, Los Angeles, CA, 90095, USA.
Marta EpeldeguiUCLA AIDS Institute and David Geffen School of Medicine, University of California, Los Angeles, Biomedical Sciences Research Building Room 173, Los Angeles, CA, 90095, USA. mepeldegui@mednet.ucla.edu.
University of California, Los Angeles · USBlack AIDS Institute · USUniversity of Arkansas for Medical Sciences · USMount Sinai Hospital · USSidney Kimmel Comprehensive Cancer Center · US

Funding

Consortium for Advancing Management and Prevention of Cancer in People with HIVUM1CA121947 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Joseph A. Sparano · 2015 to 2026
$253.7M
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
University of Southern CaliforniaU01CA121947 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MITSUYASU, RONALD T. · 2006 to 2014
$54.7M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018
$39.9M
The Role of Follicular CD8+ T Cells in Pathogenesis of AIDS-NHL.R01CA228157 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EPELDEGUI, MARTA · 2019 to 2023
$1.8M
PDL1 expression on B cells: a potential marker of pre-tumor cells in AIDS-NHLR21CA220475 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EPELDEGUI, MARTA · 2017 to 2018
$372k
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA228157NCI NIH HHS R21 CA220475NCI NIH HHS U01 CA121947NCI NIH HHS UM1 CA121947NIAID NIH HHS P30 AI028697NIH HHS R01-CA228157SNIH HHS R21-CA220475NIH HHS UM1-CA121947
6 · The paper itself

Abstract

Emerging evidence shows that tumor cells secrete extracellular vesicles (EVs) that carry bioactive cell surface markers, such as programmed death-ligand 1 (PD-L1), which can modulate immune responses and inhibit anti-tumor responses, potentially playing a role in lymphomagenesis and in promoting the growth of these cancers. In this study, we investigated the role of EVs expressing cell surface molecules associated with B cell activation and immune regulation. We measured levels of EVs derived from plasma from 57 subjects with AIDS-related non-Hodgkin lymphoma (AIDS-NHL) enrolled in the AIDS Malignancies Consortium (AMC) 034 clinical trial at baseline and post-treatment with rituximab plus concurrent infusional EPOCH chemotherapy. We found that plasma levels of EVs expressing PD-L1, CD40, CD40L or TNF-RII were significantly reduced after cancer treatment. AIDS-NHL patients with the diffuse large B cell lymphoma (DLBCL) tumor subtype had decreased plasma levels of EVs bearing PD-L1, compared to those with Burkitt's lymphoma. CD40, CD40L and TNF-RII-expressing EVs showed a significant positive correlation with plasma levels of IL-10, CXCL13, sCD25, sTNF-RII and IL-18. Our results suggest that patients with AIDS-NHL have higher levels of EVs expressing PD-L1, CD40, CD40L or TNF-RII in circulation before cancer treatment and that levels of these EVs are associated with levels of biomarkers of microbial translocation and inflammation.

Indexed as

Acquired Immunodeficiency SyndromeExtracellular VesiclesLymphoma, AIDS-RelatedB7-H1 AntigenCD40 AntigensCD40 LigandHumansReceptors, Tumor Necrosis Factor, Type IIB7-H1 AntigenCD274 protein, humanCD40 AntigensCD40 LigandReceptors, Tumor Necrosis Factor, Type II

Identifiers

PMID35655072
PMCPMC9163074
OpenAlexW4281637682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.